PT-141 / Bremelanotide: Melanocortin Agonist for Hypoactive Sexual Desire Disorder — Regulatory and Clinical Evidence

Overview

Bremelanotide (originally designated PT-141) is a cyclic heptapeptide melanocortin receptor agonist (active at MC3R and MC4R) derived from research into Melanotan II. It is the first and only melanocortin-based therapy to receive regulatory approval for sexual dysfunction, marketed as Vyleesi for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Clinical Evidence

Phase 3 RECONNECT Trials

Two double-blind, placebo-controlled Phase 3 trials (the RECONNECT program) evaluated subcutaneous bremelanotide in premenopausal women with HSDD. Patients self-administered bremelanotide on demand prior to anticipated sexual activity. The trials used validated patient-reported outcomes including the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO).

Reported results demonstrated statistically significant improvements over placebo in desire (FSFI desire domain) and reduction in distress related to low sexual desire (FSDS-DAO). The therapeutic benefit, while statistically significant, was modest in magnitude, and the FDA label notes that the mechanism of action in HSDD is not fully established.

Regulatory Approval

Bremelanotide was approved by the FDA in 2019 for premenopausal HSDD. Approval was based on the RECONNECT Phase 3 program. It is administered as a subcutaneous autoinjector and carries a boxed warning for blood pressure increases.

Mechanism of Action

Bremelanotide acts centrally as an agonist at melanocortin receptors (MC3R > MC4R), hypothetically modulating neural circuits involved in sexual motivation and arousal in the hypothalamus. The precise mechanism by which it improves sexual desire in HSDD is not fully characterized.

Safety Considerations

Common adverse events include nausea (frequent and dose-limiting), flushing, injection site reactions, and headache. A boxed warning addresses transient increases in blood pressure, and use is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. It is not recommended for patients taking oral naltrexone due to pharmacodynamic interaction.

Evidence Assessment

PT-141 / bremelanotide is an FDA-approved drug supported by a full registrational Phase 3 clinical program. It represents the highest evidence tier within the melanocortin sexual dysfunction category. The therapeutic effect is modest, and safety considerations (particularly blood pressure) constrain its use.